查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594389

NDDS 癌症治疗市场：按类型、给药方式、给药途径、应用和最终用户分类 - 全球预测 2025-2030

NDDS in Cancer Therapy Market by Type (Dendrimers, Liposomes, Micelles), Mode (Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, Targeted Drug Delivery Systems), Route of Administration, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，NDDS在癌症治疗领域的市值为104.1亿美元，预计到2024年将达到117.5亿美元，复合年增长率为13.28%，到2030年将达到249.4亿美元。

癌症治疗中的新型药物传输系统 (NDDS) 是一种变革性方法，旨在提高与癌症治疗相关的疗效、安全性和患者体验。这些系统包括脂质体、奈米颗粒和单株抗体等先进方法，可将治疗药物标靶递送并控制释放到肿瘤部位，从而将常规化疗常见的副作用降至最低。对 NDDS 的需求源于癌症盛行率的不断上升以及对更有效、毒性更低的治疗方法的迫切需求。 NDDS 的最终用途正在扩展到各种最终用途领域，包括医院、诊所和研究机构，其中精准医疗正变得越来越重要。

主要市场统计
基准年[2023] 104.1亿美元
预测年份 [2024] 117.5亿美元
预测年份 [2030] 249.4亿美元
复合年增长率（%） 13.28%

推动 NDDS 在癌症治疗中成长的关键因素包括给药系统的技术进步、个人化医疗意识的提高以及製药公司研发投资的增加。此外，对创新治疗方法的监管支持和生技药品的不断采用也增加了市场潜力。然而，市场面临着高开发成本、复杂的监管途径以及与产品製造和检验相关的复杂性等挑战。

可以透过专注于开发生物分解性和生物相容性的输送系统来抓住机会，这些系统有望降低毒性风险。创新还可以致力于整合人工智慧和机器学习，以提高药物输送的精确度。与学术机构合作进行突破性研究可以带来策略进步。此外，向医疗需求未满足的新兴市场扩张具有巨大的成长潜力。

然而，市场成长也可能受到技术复杂性和创新解决方案上市时间长的阻碍。为了克服这些挑战，相关人员必须投资于持续的研究和开发，并与监管机构保持强有力的合作，以简化核准流程。市场的动态本质需要不断适应，因此保持领先技术趋势对于持续成长和竞争力至关重要。

市场动态：针对快速发展的癌症治疗 NDDS 市场揭示的关键市场见解

供需的动态交互作用正在改变 NDDS 在癌症治疗中的市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球癌症盛行率上升
    • 对 NDDS 提高药物溶解度和降低毒性的需求日益增长
    • 加速投资开发新型癌症药物输送系统
  • 市场限制因素
    • 意识有限且成本高昂
  • 市场机会
    • 政府措施不断涌现，加上优惠的报销政策
    • 先进抗癌奈米药物传输系统的持续研究活动
  • 市场挑战
    • 缺乏技术精湛、经验丰富的医疗专业人员

波特五力：开拓 NDDS 癌症治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解癌症治疗市场 NDDS 的外部影响

外部宏观环境因素在塑造 NDDS 在癌症治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解癌症治疗 NDDS 市场的竞争状况

对 NDDS 在癌症治疗市场中的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

NDDS 市场 FPNV 定位矩阵癌症治疗供应商绩效评估

FPNV定位矩阵是评估癌症治疗市场NDDS供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与推荐的癌症治疗方法，为 NDDS 市场的成功指明道路

对于旨在加强在全球市场的影响力的公司来说，对癌症治疗市场 NDDS 进行策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地的癌症发生率正在上升
      • NDDS 提高药物溶解度和降低毒性的需求日益增长
      • 加速投资开发新型癌症药物输送系统
    • 抑制因素
      • 缺乏意识和参与造成巨大成本
    • 机会
      • 政府新措施与优惠报销政策结合
      • 先进抗癌奈米药物传输系统的研究活动
    • 任务
      • 缺乏技术精湛、经验丰富的医疗专业人员
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第 6 章 NDDS 癌症治疗市场：按类型

  • 树状聚合物
  • 脂质体
  • 胶束
  • 奈米粒子

第7章癌症治疗市场中的NDDS（按模式）

  • 受管制药物传输系统
  • 调控药物传输系统
  • 标靶给药系统

第 8 章 NDDS 癌症治疗市场：依给药途径

  • 注射给药系统
  • 口服给药系统
  • 肺部给药系统
  • 经皮给药系统

第 9 章 NDDS 癌症治疗市场：依应用分类

  • 脑肿瘤
  • 乳癌
  • 肺癌
  • 胰臟癌

第 10 章 NDDS 癌症治疗市场：依最终使用者分类

  • 门诊手术中心
  • 医院
  • 专科诊所

第11章 NDDS在美洲癌症治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区癌症治疗NDDS市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲癌症治疗的 NDDS 市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AstraZeneca
  • Boston Scientific Corporation
  • Cospheric LLC
  • Enable Injections
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Merit Medical Systems
  • MO-SCI Corporation
  • Novartis AG
  • Pacira BioSciences, Inc.
  • Pfizer Inc.
  • Samyang Holdings Corporation
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • West Pharmaceutical Services, Inc.
Product Code: MRR-521BAA36EBB7

The NDDS in Cancer Therapy Market was valued at USD 10.41 billion in 2023, expected to reach USD 11.75 billion in 2024, and is projected to grow at a CAGR of 13.28%, to USD 24.94 billion by 2030.

The Novel Drug Delivery Systems (NDDS) in cancer therapy represent a transformative approach aimed at improving the efficacy, safety, and patient experience associated with cancer treatment. These systems encompass advanced methods like liposomes, nanoparticles, and monoclonal antibodies, offering targeted delivery and controlled release of therapeutic agents at tumor sites, minimizing the adverse effects commonly associated with traditional chemotherapy. The necessity for NDDS arises from the increasing prevalence of cancer and the compelling demand for more effective and less toxic treatment modalities. Its applications extend across various end-use sectors, including hospitals, clinics, and research institutes, where precision medicine is increasingly prioritized.

KEY MARKET STATISTICS
Base Year [2023] USD 10.41 billion
Estimated Year [2024] USD 11.75 billion
Forecast Year [2030] USD 24.94 billion
CAGR (%) 13.28%

Key factors driving the growth of NDDS in cancer therapy include technological advancements in drug delivery systems, growing awareness about personalized medicine, and increased R&D investments by pharmaceutical companies. Additionally, regulatory support for innovative treatment options and the rising adoption of biologics are enhancing the market potential. However, the market faces challenges such as high development costs, complex regulatory pathways, and the intricacies involved in product manufacturing and validation.

Opportunities can be seized by focusing on the development of biodegradable and bio-compatible delivery systems, which are anticipated to mitigate risks of toxicity. Innovation could be directed towards the integration of artificial intelligence and machine learning to enhance precision in drug delivery. Collaborations with academic institutions for groundbreaking research can provide strategic advancements. Furthermore, expanding into emerging markets with unmet medical needs presents vast growth potential.

However, the market's growth could be hindered by technological complexities and the prolonged time-to-market for innovative solutions. To navigate these challenges, stakeholders should invest in continuous research and development, while also maintaining strong collaborations with regulatory bodies to streamline approval processes. The dynamic nature of the market requires constant adaptation, and staying ahead of technological trends will be crucial for sustained growth and competitiveness.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving NDDS in Cancer Therapy Market

The NDDS in Cancer Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer across the globe
    • Increasing need of NDDS to imrove drug solubility and reduce toxicity
    • Accelerating investments for development of novel drug delivery systems for cancer
  • Market Restraints
    • Limited awareness and involvement of huge cost
  • Market Opportunities
    • Emerging government initiatives coupled with favorable reimbursement policies
    • Ongoing research activities for advanced anti-cancer nano drug delivery system
  • Market Challenges
    • Dearth of skilled and experienced medical professionals

Porter's Five Forces: A Strategic Tool for Navigating the NDDS in Cancer Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the NDDS in Cancer Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the NDDS in Cancer Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the NDDS in Cancer Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the NDDS in Cancer Therapy Market

A detailed market share analysis in the NDDS in Cancer Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the NDDS in Cancer Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the NDDS in Cancer Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the NDDS in Cancer Therapy Market

A strategic analysis of the NDDS in Cancer Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the NDDS in Cancer Therapy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca, Boston Scientific Corporation, Cospheric LLC, Enable Injections, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Merit Medical Systems, MO-SCI Corporation, Novartis AG, Pacira BioSciences, Inc., Pfizer Inc., Samyang Holdings Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., and West Pharmaceutical Services, Inc..

Market Segmentation & Coverage

This research report categorizes the NDDS in Cancer Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Dendrimers, Liposomes, Micelles, and Nanoparticles.
  • Based on Mode, market is studied across Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, and Targeted Drug Delivery Systems.
  • Based on Route of Administration, market is studied across Injectable Drug Delivery Systems, Oral Drug Delivery Systems, Pulmonary Drug Delivery Systems, and Transdermal Drug Delivery Systems.
  • Based on Application, market is studied across Brain Cancer, Breast Cancer, Lung Cancer, and Pancreatic Cancer.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer across the globe
      • 5.1.1.2. Increasing need of NDDS to imrove drug solubility and reduce toxicity
      • 5.1.1.3. Accelerating investments for development of novel drug delivery systems for cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and involvement of huge cost
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging government initiatives coupled with favorable reimbursement policies
      • 5.1.3.2. Ongoing research activities for advanced anti-cancer nano drug delivery system
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of skilled and experienced medical professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. NDDS in Cancer Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Dendrimers
  • 6.3. Liposomes
  • 6.4. Micelles
  • 6.5. Nanoparticles

7. NDDS in Cancer Therapy Market, by Mode

  • 7.1. Introduction
  • 7.2. Controlled Drug Delivery Systems
  • 7.3. Modulated Drug Delivery Systems
  • 7.4. Targeted Drug Delivery Systems

8. NDDS in Cancer Therapy Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable Drug Delivery Systems
  • 8.3. Oral Drug Delivery Systems
  • 8.4. Pulmonary Drug Delivery Systems
  • 8.5. Transdermal Drug Delivery Systems

9. NDDS in Cancer Therapy Market, by Application

  • 9.1. Introduction
  • 9.2. Brain Cancer
  • 9.3. Breast Cancer
  • 9.4. Lung Cancer
  • 9.5. Pancreatic Cancer

10. NDDS in Cancer Therapy Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas NDDS in Cancer Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific NDDS in Cancer Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa NDDS in Cancer Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AstraZeneca
  • 3. Boston Scientific Corporation
  • 4. Cospheric LLC
  • 5. Enable Injections
  • 6. GlaxoSmithKline PLC
  • 7. Johnson & Johnson Services, Inc.
  • 8. Merck & Co., Inc.
  • 9. Merit Medical Systems
  • 10. MO-SCI Corporation
  • 11. Novartis AG
  • 12. Pacira BioSciences, Inc.
  • 13. Pfizer Inc.
  • 14. Samyang Holdings Corporation
  • 15. Sanofi S.A.
  • 16. Teva Pharmaceutical Industries Ltd.
  • 17. West Pharmaceutical Services, Inc.

LIST OF FIGURES

  • FIGURE 1. NDDS IN CANCER THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. NDDS IN CANCER THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NDDS IN CANCER THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NDDS IN CANCER THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CONTROLLED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODULATED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ORAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PULMONARY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TRANSDERMAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 240. NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2023